Chikungunya on the move

doi:10.1016/j.pt.2014.12.008

Trends in Parasitology

Volume 31, Issue 2, February 2015, Pages 43-45

https://doi.org/10.1016/j.pt.2014.12.008 Get rights and content

In December 2013, chikungunya virus (CHIKV) transmission was reported for the first time in the Americas. Since then it has spread quickly, with more than 1 million suspected and confirmed cases being reported in one year, where previously there were only sporadic travel-related cases. Transmission patterns suggest that the epidemic in the southern hemisphere is only beginning and that chikungunya will not go away anytime soon.

References (15)

M.C. Robinson
An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features
Trans. R. Soc. Trop. Med. Hyg.
(1955)
K. Laras
Tracking the re-emergence of epidemic chikungunya virus in Indonesia
Trans. R. Soc. Trop. Med. Hyg.
(2005)
G. Rezza
Infection with chikungunya virus in Italy: an outbreak in a temperate region
Lancet
(2007)
I. Leparc-Goffart
Chikungunya in the Americas
Lancet
(2014)
R.W. Ross
The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic
J. Hyg. (Lond.)
(1956)
Preparedness and Response for Chikungunya Virus Introduction in the Americas
(2011)
S.K. Lam
Chikungunya infection – an emerging disease in Malaysia
Southeast Asian J. Trop. Med. Public Health
(2001)

There are more references available in the full text version of this article.

Cited by (53)

Elucidating cellular interactome of chikungunya virus identifies host dependency factors
2023, Virologica Sinica
Chikungunya virus (CHIKV) is a re-emerging mosquito-transmitted RNA virus causing joint and muscle pain. To better understand how CHIKV rewires the host cell and usurps host cell functions, we generated a systematic CHIKV-human protein-protein interaction map and revealed several novel connections that will inform further mechanistic studies. One of these novel interactions, between the viral protein E1 and STIP1 homology and U-box containing protein 1 (STUB1), was found to mediate ubiquitination of E1 and degrade E1 through the proteasome. Capsid associated with G3BP1, G3BP2 and AAA+ ATPase valosin-containing protein (VCP). Furthermore, VCP inhibitors blocked CHIKV infection, suggesting VCP could serve as a therapeutic target. Further work is required to fully understand the functional consequences of these interactions. Given that CHIKV proteins are conserved across alphaviruses, many virus-host protein-protein interactions identified in this study might also exist in other alphaviruses. Construction of interactome of CHIKV provides the basis for further studying the function of alphavirus biology.
Vaccine value profile for Chikungunya
2023, Vaccine
Chikungunya virus (CHIKV) a mosquito-borne alphavirus is the causative agent of Chikungunya (CHIK), a disease with low mortality but high acute and chronic morbidity resulting in a high overall burden of disease. After the acute disease phase, chronic disease including persistent arthralgia is very common, and can cause fatigue and pain that is severe enough to limit normal activities. On average, around 40% of people infected with CHIKV will develop chronic arthritis, which may last for months or years. Recommendations for protection from CHIKV focus on infection control through preventing mosquito proliferation. There is currently no licensed antiviral drug or vaccine against CHIKV. Therefore, one of the most important public health impacts of vaccination would be to decrease burden of disease and economic losses in areas impacted by the virus, and prevent or reduce chronic morbidity associated with CHIK. This benefit would particularly be seen in Low and Middle Income Countries (LMIC) and socio-economically deprived areas, as they are more likely to have more infections and more severe outcomes.
This ‘Vaccine Value Profile’ (VVP) for CHIK is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of vaccines in the development pipeline and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the CHIK VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.
Visualization of scientific collaboration and themes for arbovirus disease in the caribbean: A forty-year trend analysis with focus on dengue, Zika and Chikungunya
2022, Travel Medicine and Infectious Disease
Citation Excerpt :
CHIKV and ZIKV both emerged recently in the Caribbean, causing large epidemics starting in December 2013 [8] and in May 2015 [9], respectively. The CHIKV epidemic spread through the Caribbean and the entire American continent, resulting in more than one million confirmed infections by December 2014 [10]. The number of cases per 1000 inhabitants per year was particularly high for CHIKV between 2013 and 2017 in Montserrat (186), St. Lucia (80), Martinique (71) and Guadeloupe (77).
The (re-)emergence of arboviruses in the Caribbean, and worldwide, is a major public health issue of concern to all scientific research stakeholders. This study aimed to use bibliometric analysis to identify the contribution of Caribbean countries to scientific production regarding the three arboviruses with the greatest impact, namely zika, chikungunya and dengue.
Bibliographic data related to arbovirus diseases were collected from three international databases (Web of Science, Pubmed, and Scopus), filtered by Caribbean islands of affiliation. VosViewer was used to identify scientific connections between countries or institutions and to identify research themes.
The dataset comprised 1332 indexed articles, with 50% of articles categorized in the top quartile of quality. Cuba was found to lead research on dengue, with a total of 300 articles, and 18 international connections. The USA-Puerto Rico duo was found to be the leader on emerging arboviruses (Zika and Chikungunya), followed by a predominantly French-language cluster (mainland France, Guadeloupe, Martinique). Key research topics were related to clinical presentations, epidemiology, and research on mosquito-borne viruses
Co-authorship network analysis on emerging arboviruses revealed the dynamics of collaboration, and provides insights into Caribbean collaborations that deserve to be created and consolidated in case of resurgence of new arbovirus epidemics.
Intravital imaging of skin infections
2020, Cellular Immunology
Citation Excerpt :
With an increasing array of immunological and molecular tools available, and the development of static, high-dimensional quantitative imaging techniques such as histocytometry [69], skin pathogens that have received little or no attention will likely be the focus of comprehensive studies that incorporate intravital imaging. Of particular relevance are arthropod-borne viruses (arboviruses), which in recent years have caused large outbreaks and continue to burden public health systems with ongoing epidemics: arboviruses such as Dengue, Chikungunya and Zika viruses are the target of several worldwide vaccine development initiatives, but little work has been done to identify the mechanisms of immune responses following skin infection that lead to systemic dissemination and disease [70,71]. In cases like these, the use of intravital imaging would be of immense benefit, considering the substantial technological advances and the resources available to date to integrate functional, quantitative and qualitative analysis.
Intravital imaging of cutaneous immune responses has revealed intricate links between the skin’s structural properties, the immune cells that reside therein, and the carefully orchestrated migratory dynamics that enable rapid sensing and subsequent elimination of skin pathogens. In particular, the development of 2-photon intravital microscopy (2P-IVM), which enables the excitation of fluorescent molecules within deep tissue with minimal light scattering and tissue damage, has proven an invaluable tool in the characterization of different cell subset’s roles in skin infection. The ability to visualize cells, tissue structures, pathogens and track migratory dynamics at designated times following infection, or during inflammatory responses has been crucial in defining how immune responses in the skin are coordinated, either locally or in concert with circulating immune cells. Skin pathogens affect millions of people worldwide, and skin infections leading to cutaneous pathology have a considerable impact on the quality of life and longevity of people affected. In contrast, pathogens that infect the skin to later cause systemic illness, such as malaria parasites and a variety of arthropod-borne viruses, or infection in distant anatomical sites are a significant cause of morbidity and mortality worldwide. Here, we review recent advances and seminal studies that employed intravital imaging to characterize key immune response mechanisms in the context of viral, bacterial and parasitic skin infections, and provide insights on skin pathogens of global significance that would benefit from such investigative approaches.
Neutralizing Antibodies Inhibit Chikungunya Virus Budding at the Plasma Membrane
2018, Cell Host and Microbe
Neutralizing antibodies (NAbs) are traditionally thought to inhibit virus infection by preventing virion entry into target cells. In addition, antibodies can engage Fc receptors (FcRs) on immune cells to activate antiviral responses. We describe a mechanism by which NAbs inhibit chikungunya virus (CHIKV), the most common alphavirus infecting humans, by preventing virus budding from infected human cells and activating IgG-specific Fcγ receptors. NAbs bind to CHIKV glycoproteins on the infected cell surface and induce glycoprotein coalescence, preventing budding of nascent virions and leaving structurally heterogeneous nucleocapsids arrested in the cytosol. Furthermore, NAbs induce clustering of CHIKV replication spherules at sites of budding blockage. Functionally, these densely packed glycoprotein-NAb complexes on infected cells activate Fcγ receptors, inducing a strong, antibody-dependent, cell-mediated cytotoxicity response from immune effector cells. Our findings describe a triply functional antiviral pathway for NAbs that might be broadly applicable across virus-host systems, suggesting avenues for therapeutic innovation through antibody design.
Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease
2018, Biochimie
Chikungunya virus (CHIKV), a mosquito-borne pathogenic virus that reemerged and caused epidemic in the Indian Ocean island of La Réunion, is a potential public health threat. Currently there is no antiviral drug or vaccine commercially available for the treatment of chikungunya fever, which necessitates the urge for an effective antiviral therapy for chikungunya treatment. In the present study, a FRET based protease assay was used to analyze the proteolytic activity of chikungunya nsP2 protease (CHIKV nsP2pro) - an essential viral enzyme, with fluorogenic substrate peptide. This protease assay was used to assess the inhibitory activity of Pep-I (MMsINC^® database ID MMs03131094) and Pep-II (MMsINC^® database ID MMs03927237), peptidomimetic compounds identified in a previous study by our group. Both compounds inhibited CHIKV nsP2pro with half maximal inhibition concentration (IC₅₀) values of ∼34 μM and ∼42 μM, respectively. Kinetic studies showed that the inhibition constant (K_i) value is 33.34 ± 2.53 μM for Pep-I and 45.89 ± 4.38 μM for Pep-II. Additionally, these two compounds significantly inhibited CHIKV replication in BHK-21 cells at concentrations much lower than their cytotoxic concentrations. Intriguingly, these compounds did not show inhibitory effect on Sindbis virus. This suggests that Pep-I and Pep-II compounds identified as CHIKV nsP2 substrate peptidomimetics, specifically inhibit CHIKV replication.

View all citing articles on Scopus

View full text

Published by Elsevier Ltd.

Trends in Parasitology

Science & SocietyChikungunya on the move

Trans. R. Soc. Trop. Med. Hyg.

Trans. R. Soc. Trop. Med. Hyg.

Lancet

Lancet

The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic

J. Hyg. (Lond.)

Preparedness and Response for Chikungunya Virus Introduction in the Americas

Chikungunya infection – an emerging disease in Malaysia

Southeast Asian J. Trop. Med. Public Health

Science & Society
Chikungunya on the move